INFI

Infinity Pharmaceuticals (INFI)

Infinity Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:INFI

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2023/09/13	21 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/09/13	07 : 20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/09/12	05 : 09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/09/02	05 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/08/11	05 : 32	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/26	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/26	05 : 05	Business Wire	Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/24	21 : 35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/24	21 : 30	Business Wire	Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/15	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/15	02 : 00	Business Wire	Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/10	21 : 30	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/10	21 : 30	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/10	21 : 30	Business Wire	Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN)	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/05	21 : 30	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/05	21 : 30	Business Wire	ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/04	05 : 57	Edgar (US Regulatory)	Form 425 - Prospectuses and communications, business combinations	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/04	05 : 55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/03	21 : 31	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/07/01	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/06/29	19 : 01	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/06/27	21 : 31	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/06/21	21 : 32	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/06/20	21 : 31	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/06/20	21 : 01	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/06/17	01 : 34	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/06/16	21 : 32	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/06/16	01 : 08	Business Wire	MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/06/15	21 : 00	Business Wire	MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates	NASDAQ:INFI	Infinity Pharmaceuticals Inc
2023/06/07	05 : 44	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:INFI	Infinity Pharmaceuticals Inc